Danaher Corporation $DHR Shares Newly Purchased by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments purchased 214,671 Danaher shares worth approximately $47.6 million during the third quarter. Institutional investors collectively own 79.05% of DHR.
• Analysts maintain a generally positive outlook, with 18 Buy ratings and five Holds producing a consensus “Moderate Buy” rating and an average price target of $242.91.
• Danaher exceeded quarterly earnings expectations, reporting $2.11 in EPS versus the $1.92 consensus, while revenue rose 8.3% year over year to $6.55 billion. The company also declared a quarterly dividend of $0.40 per share.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 214,671 shares of the conglomerate's stock, valued at approximately $47,560,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Prime Capital Investment Advisors LLC raised its stake in shares of Danaher by 0.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate's stock worth $2,039,000 after purchasing an additional 45 shares during the last quarter. Essential Investment Partners LLC grew its position in Danaher by 34.6% in the 3rd quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate's stock valued at $39,000 after buying an additional 45 shares during the last quarter. Veery Capital LLC grew its position in Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate's stock valued at $350,000 after buying an additional 48 shares during the last quarter. Studio Investment Management LLC increased its stake in Danaher by 3.3% in the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate's stock valued at $302,000 after buying an additional 51 shares during the period. Finally, Meridian Financial Partners LLC increased its stake in Danaher by 1.2% in the 3rd quarter. Meridian Financial Partners LLC now owns 4,636 shares of the conglomerate's stock valued at $1,073,000 after buying an additional 56 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of the stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the completion of the transaction, the chief accounting officer directly owned 9,107 shares of the company's stock, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Robert W. Baird increased their price target on shares of Danaher from $246.00 to $254.00 and gave the company an "outperform" rating in a research report on Thursday, October 22nd. Wells Fargo & Company cut their target price on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. UBS Group reaffirmed a "buy" rating and issued a $260.00 price objective on shares of Danaher in a research report on Thursday, October 22nd. Finally, Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $242.91.

Danaher Stock Down 0.0%

NYSE:DHR opened at $232.22 on Monday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a current ratio of 1.63, a quick ratio of 1.29 and a debt-to-equity ratio of 0.45. The stock has a 50 day moving average of $218.92 and a 200-day moving average of $201.77. The firm has a market capitalization of $163.37 billion, a PE ratio of 38.01, a price-to-earnings-growth ratio of 2.92 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter in the previous year, the company posted $1.89 earnings per share. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. Analysts predict that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher's dividend payout ratio (DPR) is 26.19%.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.